scholarly journals 19144 Effect of Mesalamine on Metabolic Syndrome risk factors in Ulcerative Colitis Patients: A Retrospective study

2021 ◽  
pp. 1-2
Author(s):  
Eliseo Castillo ◽  
Graziella Rangel Paniz ◽  
Fray Arroyo-Mercado ◽  
Christina L. Ling ◽  
Harry Snow ◽  
...  
Keyword(s):  
Risk Factors ◽  
Ulcerative Colitis ◽  
Metabolic Syndrome ◽  
Retrospective Study

scholarly journals Assessment of mesalamine in the alterations of metabolic parameters in comorbid ulcerative colitis and metabolic syndrome patients: A retrospective study

2021 ◽  
Author(s):  
Graziella Rangel Panez ◽  
Fray M Arroyo-Mercado ◽  
Christina L Ling ◽  
E. Eunice Choi ◽  
Harry E Snow ◽  
...  
Keyword(s):  
Risk Factors ◽  
Ulcerative Colitis ◽  
Metabolic Syndrome ◽  
Index Date ◽  
Retrospective Chart Review ◽  
Hdl Cholesterol ◽  
Analysis Of Covariance ◽  
Metabolic Parameters ◽  
Protein Levels ◽  
Glucose Levels

BACKGROUND & AIMS: It is unclear how the gut targeting medication mesalamine alters metabolic parameters associated with Metabolic Syndrome (MetS). We completed a retrospective analysis on ulcerative colitis (UC) and MetS comorbid patients receiving mesalamine to examine the effects of mesalamine on the metabolic risk factors associated with MetS. METHODS: We performed a retrospective chart review using Cerner Health Facts (from July 2007 to July 2017). We identified UC patients with a MetS comorbidity and who were prescribed mesalamine within +/- 7 days of an encounter in which they were diagnosed with UC. We then collected the patients blood pressure, labs, and body measurement index (BMI) for each of these patient at the index date and the closest values to 12 months after the index date. We used analysis of covariance (ANCOVA) to determine the effect of mesalamine therapy in patients with both UC and MetS on the metabolic parameters after 12 months of treatment compared to baseline. RESULTS: Our search of Cerner Health Facts identified 6,197 UC patients with concomitant MetS who were prescribed mesalamine. Of these individuals, 48% were female and 52% were male and within this cohort 88.3% received oral mesalamine and 11.7% received mesalamine via the rectal route. Oral mesalamine reduced fasting glucose levels and increased HDL cholesterol in these patients. C-reactive protein levels and erythrocyte sedimentation rate were also significantly reduced. Rectal mesalamine only reduced BMI. Further analysis revealed several MetS conditions risk factors were further improved when mesalamine was taken in the absence of medication for hypertension, hyperglycemia or dyslipidemia. CONCLUSION: In a retrospective chart study of UC-MetS patients, we found oral mesalamine improved several metabolic parameters associated with MetS. Our findings suggest the PPAR agonist mesalamine that targets the gastrointestinal tract could prove beneficial in improving hypertension, hyperglycemia and dyslipidemia.

scholarly journals Risk Factors of Metabolic Syndrome Among Patients Receiving Antipsychotics: A Retrospective Study

2019 ◽  
Vol 56 (4) ◽  
pp. 760-770 ◽  
Author(s):  
Samer Hammoudeh ◽  
Hawra Al Lawati ◽  
Suhaila Ghuloum ◽  
Huma Iram ◽  
Arij Yehya ◽  
...  
Keyword(s):  
Risk Factors ◽  
Metabolic Syndrome ◽  
Body Mass Index ◽  
Retrospective Study ◽  
Mentally Ill ◽  
First Generation ◽  
Clinical Status ◽  
Metabolic Effects ◽  
Retrospective Data ◽  
Second Generation Antipsychotics

AbstractThis study aimed to assess the differential effects of first-generation (FGA) and second-generation antipsychotics (SGA) on the prevalence of risk factors for metabolic syndrome among mentally ill patients in Qatar. We also wanted to check if there is proper adherence with the guidelines for prescribing antipsychotics and the monitoring of metabolic effects in this population. We collected the available retrospective data (socio-demographic, psychiatric, anthropometric, and metabolic measures) from the records of 439 patients maintained on antipsychotics. The majority were males, married, employed, having a psychotic disorder, and receiving SGA. Patients on SGA showed more obesity, higher BP, and more elevated triglycerides compared to those on FGA. The prevalence of the abnormal metabolic measures was high in this sample, but those on SGA showed a significantly higher prevalence of abnormal body mass index and BP. Obesity and hypertension were common in patients maintained on antipsychotics, especially those on SGA. Polypharmacy was common, and many metabolic measures were not monitored properly in those maintained on antipsychotics. More prospective studies with guided monitoring of the patients' clinical status and metabolic changes are needed to serve better this population of patients.

Sign in / Sign up

Export Citation Format

Share Document